Novo Holdings Vaxcyte, Inc. Transaction History

Novo Holdings

$1.43 Billion
Q3 2024

A detailed history of Novo Holdings transactions in Vaxcyte, Inc. stock. As of the latest transaction made, Novo Holdings holds 750,000 shares of PCVX stock, worth $79.6 Million. This represents 5.99% of its overall portfolio holdings.

Number of Shares

750,000

Previous 950,000 21.05%

Holding current value

$79.6 Million

Previous $71.7 Million 19.37%

% of portfolio

5.99%

Previous 5.12%

10 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 24, 2024	SELL	$70.52 - $117.12 $14.1 Million - $23.4 Million	-200,000 Reduced 21.05%	750,000 $85.6 Million
Q2 2024 Aug 14, 2024	BUY	$60.06 - $78.77 $6.31 Million - $8.27 Million	105,000 Added 12.43%	950,000 $71.7 Million
Q2 2023 Aug 14, 2023	BUY	$34.66 - $54.07 $3.47 Million - $5.41 Million	100,000 Added 13.42%	845,000 $42.2 Million
Q1 2023 May 15, 2023	BUY	$36.27 - $47.2 $725,400 - $944,000	20,000 Added 2.76%	745,000 $27.9 Million
Q4 2022 Feb 14, 2023	SELL	$20.58 - $47.95 $2.03 Million - $4.73 Million	-98,705 Reduced 11.98%	725,000 $34.8 Million
Q2 2022 Aug 15, 2022	BUY	$17.68 - $26.58 $14.6 Million - $21.9 Million	823,705 New	823,705 $17.9 Million
Q2 2021 Aug 16, 2021	SELL	$16.45 - $24.06 $6.86 Million - $10 Million	-416,937 Closed	0 $0
Q4 2020 Feb 16, 2021	SELL	$26.57 - $51.74 $6.23 Million - $12.1 Million	-234,318 Reduced 35.98%	416,937 $11.1 Million
Q3 2020 Nov 16, 2020	SELL	$26.5 - $55.4 $6.11 Million - $12.8 Million	-230,643 Reduced 26.15%	651,255 $32.2 Million
Q2 2020 Aug 14, 2020	BUY	$26.15 - $35.45 $23.1 Million - $31.3 Million	881,898 New	881,898 $27.9 Million

Others Institutions Holding PCVX

# of Institutions

289

Shares Held

110M

Call Options Held

246K

Put Options Held

98.7K

View Full List

About Vaxcyte, Inc.

Ticker PCVX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 59,315,100
Market Cap $6.3B
Description
Vaxcyte, Inc., a clinical-stage biotechnology vaccine company, develops novel protein vaccines to prevent or treat bacterial infectious diseases. Its lead vaccine candidate is VAX-24, a 24-valent investigational pneumococcal conjugate vaccine that is in Phase 1/2 clinical trials to treat invasive pneumococcal disease and pneumonia. The company a...

More about PCVX

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Novo Holdings, based on Form 13F filings with the SEC.

News

Stay updated on Novo Holdings with notifications on news.

Account